CStone Pharmaceuticals (HK:2616)
:2616
Want to see HK:2616 full AI Analyst Report?
2616 Stock Chart & Stats
HK$5.34
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$5.34
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$3.80 - HK$13.15
Previous CloseN/A
Volume1.16M
Average Volume (3M)19.75M
Market Cap
HK$7.78B
Enterprise ValueHK$10.71B
Total Cash (Recent Filing)HK$919.09M
Total Debt (Recent Filing)HK$348.67M
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Aug 20, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding1,600,249,100
10 Day Avg. Volume13,736,900
30 Day Avg. Volume19,747,038
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)10.65
Price to Sales (P/S)24.38
P/FCF Ratio-20.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$9.44Price Target Upside76.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)HK$468.24M
Bulls Say, Bears Say
Bulls Say
Diverse Revenue SourcesCStone's business model combines commercial product sales with licensing/collaboration payments and potential services. This mix provides multiple durable funding channels for R&D and commercialization, reducing single-revenue dependence and supporting longer-term development financing.
Top-line Rebound In 2025A 47.7% revenue rebound in 2025 indicates recovering commercial traction and demand for marketed products. Sustained top-line growth can improve scale economics, enable reinvestment in the pipeline, and strengthen negotiating leverage with partners over the next several quarters.
Improved LeverageLower debt-to-equity reduces refinancing and liquidity risk and increases financial flexibility. An improved capital structure gives the company more runway to fund clinical programs or commercialization initiatives without immediate need for aggressive external financing.
Bears Say
Persistent Negative Cash FlowSustained negative operating and free cash flow forces reliance on external capital to fund operations and R&D. Over 2–6 months this raises financing risk, could dilute existing shareholders, and constrains the company's ability to scale commercialization or absorb trial delays.
Severe Margin DeteriorationA drastic drop in gross and net margins signals structural profitability issues—product mix shifts, pricing pressure, or rising costs. Margin volatility undermines the sustainability of the business model and makes future profitability and cash generation uncertain without corrective action.
Deep Unprofitability And Weak ReturnsPersistently negative ROE and large losses erode shareholder value and limit internal funding for drug development. Over a multi-quarter horizon this constrains strategic options, increases dependence on partners or capital markets, and heightens execution risk for pipeline and commercialization.
CStone Pharmaceuticals News
2616 FAQ
What was CStone Pharmaceuticals’s price range in the past 12 months?
CStone Pharmaceuticals lowest stock price was HK$3.80 and its highest was HK$13.15 in the past 12 months.
What is CStone Pharmaceuticals’s market cap?
CStone Pharmaceuticals’s market cap is HK$7.78B.
When is CStone Pharmaceuticals’s upcoming earnings report date?
CStone Pharmaceuticals’s upcoming earnings report date is Aug 20, 2026 which is in 76 days.
How were CStone Pharmaceuticals’s earnings last quarter?
CStone Pharmaceuticals released its earnings results on Mar 26, 2026. The company reported -HK$0.138 earnings per share for the quarter, missing the consensus estimate of -HK$0.057 by -HK$0.08.
Is CStone Pharmaceuticals overvalued?
According to Wall Street analysts CStone Pharmaceuticals’s price is currently Undervalued.
Does CStone Pharmaceuticals pay dividends?
CStone Pharmaceuticals does not currently pay dividends.
What is CStone Pharmaceuticals’s EPS estimate?
CStone Pharmaceuticals’s EPS estimate is -0.22.
How many shares outstanding does CStone Pharmaceuticals have?
CStone Pharmaceuticals has 1,600,249,100 shares outstanding.
What happened to CStone Pharmaceuticals’s price movement after its last earnings report?
CStone Pharmaceuticals reported an EPS of -HK$0.138 in its last earnings report, missing expectations of -HK$0.057. Following the earnings report the stock price went up 0.145%.
Which hedge fund is a major shareholder of CStone Pharmaceuticals?
Currently, no hedge funds are holding shares in HK:2616
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CStone Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$9.44 (76.78% Upside)
HK$9.44 (76.78% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
290.90%
12-Months-Change
Fundamentals
Return on Equity
-64.78%
Trailing 12-Months
Asset Growth
2.02%
Trailing 12-Months
Company Description
CStone Pharmaceuticals
CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. The company's product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma; Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor to treat adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation; and Fisogatinib, an FGFR4 inhibitor to treat hepatocellular carcinoma. Its products also comprise CS1002, CS2006, CS3002, CS3005, CS2007, CS2008, and CS500 for solid tumors; and CS5001 for solid tumors and hematologic malignancies. The company was incorporated in 2015 and is headquartered in Shanghai, China.
2616 Stock 12 Month Forecast
Average Price Target
HK$9.44
▲(76.78% Upside)
Technical Analysis
Zai Lab Ltd
―
Alphamab Oncology
―
InnoCare Pharma Ltd.
―
CARsgen Therapeutics Holdings Ltd.
―
Ascentage Pharma Group International
―
Options Prices
Currently, No data available
---